LivingGLP1
Study S001028

The Use of Incretin-based Drugs and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration
NCT02476760
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
1417914
Start
2014-03
Primary completion
2015-04
Lead sponsor
Canadian Network for Observational Drug Effect Studies, CNODES
Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG:DPP-4 inhibitors; DRUG:GLP-1 analogs; DRUG:Insulins; DRUG:Biguanides; DRUG:Sulfonylureas; DRUG:Thiazolidinediones; DRUG:Alpha-glucosidase inhibitors; DRUG:Meglitinides
Results posted
FALSE

Registered primary outcomes

  • Hospitalization for acute pancreatitis [Patients were followed from the date of study cohort entry until hospitalization for incident acute pancreatitis, censoring, or for up to 87 months.]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0025523Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Azoulay L, JAMA internal medicine
2016Randomized trialPMID 27479930DOIregistry reference RESULT:27479930